MedTrace Logo

Examining the Effect of Burosumab on Muscle Function

NCT04146935 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-08-24

Study results available
· View outcomes & findings →

Summary

Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The investigators wish to test this hypothesis directly by measuring muscle energy when patients begin treatment with Crysvita® for the first time.

Conditions

  • X-linked Hypophosphatemia

Interventions

DRUG

Burosumab Injection [Crysvita]

Burosumab/Crysvita SC injection monthly

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Karl L Insogna, M.D. · Yale University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-13
Primary Completion
2022-08-25
Completion
2022-08-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04146935 on ClinicalTrials.gov